Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $9.2M rose 70.7% year over year, behind the +97.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 21.3% from the prior quarter. Over 3 fiscal years it compounded at +229.4% a year.
Context
- Stock-based compensation amounted to 263.5% of revenue in FY2025, up 47.0 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +70.7% toward the trailing-twelve-month pace of +97.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 26.35M USD
- Year-over-year change
- +143.5%
- 3-year CAGR
- +229.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.35M | +143.5% |
| FY2024 | 2024-12-31 | 10.82M | +209.6% |
| FY2023 | 2023-12-31 | 3.5M | +374.2% |
| FY2022 | 2022-12-31 | 737K | — |
Stock-Based Compensation vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 stock-based compensation of $30.16M is the 3rd largest of the 8 companies compared; the peer median is $12.34M.
- Its year-over-year change of +97.6% is the highest of 7, against a peer median of -4.9%.
- Over three fiscal years its annual growth of +229.4% compares with a peer median of +19.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.91M | -7.8% | +19.9% | 717.6% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $32.3M | +20.4% | — | — |
| LTM Mar 2026 | $30.16M | +97.6% | +229.4% | — | |
| LTM Mar 2026 | $15.5M | -21.9% | -3.9% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $12.34M | +54.4% | +100.6% | 371.6% |
| LTM Mar 2026 | $12.05M | -2.1% | -6.3% | 144.0% | |
| LTM Mar 2026 | $3.99M | -24.8% | +61.9% | 7.4% | |
| FY2025 | $0 | — | — | — | |
| Peer median (excluding ZBIO) | $12.34M | -4.9% | +19.9% | 257.8% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.